Astera Cancer Care
Bruno Fang currently serves as the President, Physician Manager, and Director of Clinical Research at Astera Cancer Care since April 2021. Prior experience includes positions as Managing Partner and Chairman of the Committee at Regional Cancer Care Associates from January 2012 to April 2021, and a Board Trustee role at The Wardlaw + Hartridge School from August 2017 to July 2020. Previous affiliations also include a decade as a Physician at CENTRAL JERSEY ONCOLOGY CENTER, PA, and clinical fellowships at the National Cancer Institute focusing on Hematology Oncology. Early medical training encompassed roles as Chief Resident and Resident at Jackson Memorial Hospital and Resident Doctor at Hospital das Clinicas da Faculdade de Medicina da Usp. Bruno Fang earned a Doctor of Medicine degree from USP - Universidade de São Paulo and holds a Higher National Diploma from Colégio Bandeirantes and a Middle School Diploma from Colégio Renascença.
This person is not in any teams
This person is not in any offices
Astera Cancer Care
Astera Cancer Care (ACC) is a multispecialty physician practice consisting of medical oncologists, radiation oncologists, and breast surgeons focused on the care of patients with cancer and blood disorders. ACC physicians have cared for thousands of patients in New Jersey since 1981. ACC providers currently practice at 14 distinct locations in Middlesex, Somerset, Hunterdon, Mercer, and Monmouth counties in New Jersey as well as in Bucks County, Pennsylvania. ACC offers standard and advanced therapeutics, including chemotherapy, biologic therapy, immunotherapy and radiopharmaceuticals along with a complete portfolio of radiation oncology treatment options, including proton therapy, prostate brachytherapy, and radiosurgery. The practice is one of the few private groups on the East Coast to offer patients this full array of radiation oncology treatments. Astera has a robust clinical trial platform for cancer therapy with one of the only community-based clinical trial programs in CAR-T cell therapies in the nation. The group is also a leader in value-based oncology care and alternative payment model development.